Skip to content 
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. more
| Time Frame | FBIOP | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 11.18% | 2.19% | 1.43% |
| 1-Month Return | 13.63% | -0.77% | 6.88% |
| 3-Month Return | 37.71% | -6.82% | 9.51% |
| 6-Month Return | 124.33% | -3.34% | 12.37% |
| 1-Year Return | 127.08% | 12.39% | 26.71% |
| 3-Year Return | -16.52% | 11.12% | 81.24% |
| 5-Year Return | -41.02% | 19% | 80.02% |
| 10-Year Return | -38.1% | 109.23% | 262.67% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 68.79M | 75.74M | 84.51M | 57.67M | 63.26M | [{"date":"2021-12-31","value":81.4,"profit":true},{"date":"2022-12-31","value":89.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":68.24,"profit":true},{"date":"2025-12-31","value":74.85,"profit":true}] |
| Cost of Revenue | 32.08M | 30.77M | 22.89M | 20.88M | 20.92M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.92,"profit":true},{"date":"2023-12-31","value":71.35,"profit":true},{"date":"2024-12-31","value":65.08,"profit":true},{"date":"2025-12-31","value":65.22,"profit":true}] |
| Gross Profit | 36.71M | 44.97M | 61.62M | 36.80M | 42.34M | [{"date":"2021-12-31","value":59.57,"profit":true},{"date":"2022-12-31","value":72.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":59.71,"profit":true},{"date":"2025-12-31","value":68.71,"profit":true}] |
| Gross Margin | 53.36% | 59.37% | 72.91% | 63.80% | 66.92% | [{"date":"2021-12-31","value":73.18,"profit":true},{"date":"2022-12-31","value":81.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":87.5,"profit":true},{"date":"2025-12-31","value":91.79,"profit":true}] |
| Operating Expenses | 225.25M | 248.53M | 203.96M | 147.18M | 112.56M | [{"date":"2021-12-31","value":90.63,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.07,"profit":true},{"date":"2024-12-31","value":59.22,"profit":true},{"date":"2025-12-31","value":45.29,"profit":true}] |
| Operating Income | (188.54M) | (203.56M) | (142.34M) | (110.38M) | (70.22M) | [{"date":"2021-12-31","value":-18854100000,"profit":false},{"date":"2022-12-31","value":-20356400000,"profit":false},{"date":"2023-12-31","value":-14234200000,"profit":false},{"date":"2024-12-31","value":-11037900000,"profit":false},{"date":"2025-12-31","value":-7022100000,"profit":false}] |
| Total Non-Operating Income/Expense | 9.53M | (22.14M) | (26.31M) | (21.01M) | 29.07M | [{"date":"2021-12-31","value":32.79,"profit":true},{"date":"2022-12-31","value":-76.19,"profit":false},{"date":"2023-12-31","value":-90.52,"profit":false},{"date":"2024-12-31","value":-72.28,"profit":false},{"date":"2025-12-31","value":100,"profit":true}] |
| Pre-Tax Income | (164.35M) | (213.46M) | (153.63M) | (120.54M) | (33.53M) | [{"date":"2021-12-31","value":-16435300000,"profit":false},{"date":"2022-12-31","value":-21346400000,"profit":false},{"date":"2023-12-31","value":-15363300000,"profit":false},{"date":"2024-12-31","value":-12054300000,"profit":false},{"date":"2025-12-31","value":-3353500000,"profit":false}] |
| Income Taxes | 473.00K | 449.00K | 521.00K | 312.00K | (620.00K) | [{"date":"2021-12-31","value":90.79,"profit":true},{"date":"2022-12-31","value":86.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":59.88,"profit":true},{"date":"2025-12-31","value":-119,"profit":false}] |
| Income After Taxes | (164.83M) | (213.91M) | (154.15M) | (120.86M) | (32.91M) | [{"date":"2021-12-31","value":-16482600000,"profit":false},{"date":"2022-12-31","value":-21391300000,"profit":false},{"date":"2023-12-31","value":-15415400000,"profit":false},{"date":"2024-12-31","value":-12085500000,"profit":false},{"date":"2025-12-31","value":-3291500000,"profit":false}] |
| Income From Continuous Operations | (164.83M) | (213.91M) | (182.62M) | (120.86M) | (32.91M) | [{"date":"2021-12-31","value":-16482600000,"profit":false},{"date":"2022-12-31","value":-21391300000,"profit":false},{"date":"2023-12-31","value":-18261500000,"profit":false},{"date":"2024-12-31","value":-12085500000,"profit":false},{"date":"2025-12-31","value":-3291500000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | (64.70M) | (86.58M) | (60.64M) | (46.00M) | 6.82M | [{"date":"2021-12-31","value":-949.42,"profit":false},{"date":"2022-12-31","value":-1270.36,"profit":false},{"date":"2023-12-31","value":-889.76,"profit":false},{"date":"2024-12-31","value":-674.94,"profit":false},{"date":"2025-12-31","value":100,"profit":true}] |
| EPS (Diluted) | - | - | - | (0.67) | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-66.92,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| FBIOP | |
|---|---|
| Cash Ratio | 1.60 |
| Current Ratio | 2.49 |
| Quick Ratio | 2.30 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| FBIOP | |
|---|---|
| ROA (LTM) | -26.62% |
| ROE (LTM) | -108.74% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| FBIOP | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.66 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.27 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| FBIOP | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 1.23 |
| P/B | 0.00 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Fortress Biotech Inc Pref Series A (FBIOP) share price today is $15.01
Yes, Indians can buy shares of Fortress Biotech Inc Pref Series A (FBIOP) on Vested. To buy
Yes, you can purchase fractional shares of Fortress Biotech Inc Pref Series A (FBIOP) via the Vested app. You can start investing in Fortress Biotech Inc Pref Series A (FBIOP) with a minimum investment of $1.
You can invest in shares of Fortress Biotech Inc Pref Series A (FBIOP) via Vested in three simple steps:
The 52-week high price of Fortress Biotech Inc Pref Series A (FBIOP) is $14.64. The 52-week low price of Fortress Biotech Inc Pref Series A (FBIOP) is $6.27.
The price-to-earnings (P/E) ratio of Fortress Biotech Inc Pref Series A (FBIOP) is
The price-to-book (P/B) ratio of Fortress Biotech Inc Pref Series A (FBIOP) is 0.00
The dividend yield of Fortress Biotech Inc Pref Series A (FBIOP) is 0.00%
The market capitalization of Fortress Biotech Inc Pref Series A (FBIOP) is $77.81M
The stock symbol (or ticker) of Fortress Biotech Inc Pref Series A is FBIOP
Consider the share price of Fortress Biotech Inc Pref Series A as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Fortress Biotech Inc Pref Series A has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Fortress Biotech Inc Pref Series A shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Fortress Biotech Inc Pref Series A stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Fortress Biotech Inc Pref Series A and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Fortress Biotech Inc Pref Series A stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
